Key result
Clopidogrel-aspirin for 21 days leads stroke and TIA, while ticagrelor or prasugrel leads ACS PCI.
Why the study?
Although guidelines recommend ticagrelor and prasugrel over clopidogrel for most ACS patients undergoing PCI, clopidogrel retains a pivotal role in specific coronary and cerebrovascular scenarios, motivating a synthesis of recent meta-analyses and guideline updates into a practical clinical framework.
This review synthesizes current trial evidence and 2023 ESC / 2025 ACC/AHA guidelines to define the clinical role of clopidogrel relative to ticagrelor and prasugrel across coronary and cerebrovascular disease.
Answers are grounded in this paper and cite their sources.
Supports current standards for clopidogrel-aspirin in stroke/TIA and potent P2Y12 in ACS/PCI; leaves open optimal pharmacogenomic integration in practice.
Clopidogrel (CLP) remains a cornerstone of antiplatelet therapy in the management of atherothrombotic events affecting the coronary and cerebrovascular circulations. As an irreversible thienopyridine inhibitor of the platelet P2Y12 adenosine diphosphate (ADP) receptor, CLP reduces platelet aggregation by preventing downstream activation of the glycoprotein IIb/IIIa receptor complex. It is a prodrug that requires hepatic bioactivation primarily via CYP2C19, resulting in susceptibility to pharmacogenomic variability and clinically significant drug-drug interactions. Current guidelines from the European Society of Cardiology (2023) and the American College of Cardiology/American Heart Association (2025) recommend potent P2Y12 inhibitors - ticagrelor and prasugrel - in preference to CLP for most patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI); however, CLP retains a pivotal role when potent agents are contraindicated, in elderly patients at high bleeding risk (HBR), in cerebrovascular events, and as a de-escalation target following initial potent P2Y12 inhibition. In acute ischaemic stroke and high-risk TIA, short-course DAPT with CLP and aspirin for 21 days (not prolonged beyond this period) is the evidence-based standard of care. Major clinical trials - including CAPRIE, CURE, CHANCE, POINT, and the landmark CHANCE-2 - have defined the therapeutic boundaries and limitations of CLP-based dual antiplatelet therapy (DAPT). Bleeding remains the most clinically significant adverse effect, with gastrointestinal haemorrhage the most frequent site and intracranial haemorrhage the most feared complication. This review synthesises current evidence, incorporating recent meta-analyses and guideline updates, to provide a practical, evidence-based framework for clinicians regarding the use of CLP and comparator P2Y12 inhibitors in coronary and cerebrovascular disease.
No takes yet. Share an insight, caveat, or question.
Akman et al. (2026) conducted a review in Coronary and cerebrovascular atherothrombotic events (including ACS undergoing PCI, acute ischaemic stroke, and high-risk TIA). Clopidogrel vs. Potent P2Y12 inhibitors (ticagrelor and prasugrel) was evaluated. Clopidogrel with aspirin for 21 days is the standard of care in acute ischaemic stroke and high-risk TIA, while ticagrelor and prasugrel are preferred in ACS undergoing PCI.
Synapse has enriched 10 related papers. Consider them for comparative context: